Fig. 7

Effect of PFE on the expression of PCNA in prostatic tissue. Prostatic tissues were homogenized and PCNA/β-actin protein expression was determined using western blotting: (a) expressions of PCNA and β-actin, and (b) relative ratio, relative levels of PCNA. The β-actin protein was used as a loading control for quantitative analysis. The relative ratios of protein expression were normalized to β-actin and are represented in quantitative graphs. NC (normal control group), corn oil injection (s.c.) + PBS administration (p.o.); BPH (control group), TP (3 mg/kg)/corn oil injection (s.c.) + PBS administration (p.o.); Fin (positive control group), TP (3 mg/kg)/corn oil injection (s.c.) + finasteride administration (10 mg/kg, p.o.); PFE (PFE-treated group), TP (3 mg/kg)/corn oil injection (s.c.) + PFE administration (200 mg/kg, p.o.). Data are presented as mean ± S.E.M. (n = 6). Significant differences at ^## P < 0.01 compared with the NC group. Significant differences at ^* P < 0.05 and ^** P < 0.01 compared with the BPH group. BPH, benign prostatic hyperplasia; Fin, finasteride; PBS, phosphate-buffered saline; PFE, Ponciri fructus extract; p.o., peroral; s.c., subcutaneously; PCNA, proliferating cell nuclear antigen; TP, testosterone propionate